**Section: Contact Information**

First Name: Eileen  
Last Name: Dolan  
Institution: University of Chicago  
Address 1: 900 E 57th St  
Address 2: KCBDD7100  
City: Chicago  
State/Province/Region: IL  
Country: US  
Zip/Postal Code: 60637  
Phone Number: 773-702-4441  
Alternate Phone Number:  
Email Address: edolan@medicine.bsd.uchicago.edu  

**Section: Project Requirements and Description**

**Group: Requirements to submit AOI**

A comprehensive review of previously published data has been completed.  
Yes  
The specific aims are clear and focused.  
Yes  
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator.  
Yes  
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months.  
Yes  
Project Title: GWAS of Cisplatin induced and non-cisplatin induced Hearing Loss  
Planned research population (eligibility criteria):  
Within CCSS there are 3,337 survivors of which 316 report hearing loss and 2,947 report no hearing loss. For cisplatin treated, there are 37 cases and 96 controls. For non cisplatin treated there are 259 cases and 2,729 controls. We will perform GWAS in both groups.  
Proposed specific aims:  
To perform: 1) a GWAS of self reported hearing loss in cisplatin-treated pediatric cancer survivors in CCSS and 2) a GWAS of self reported hearing loss in noncisplatin-treated pediatric cancer survivors in CCSS  
Will the project require non-CCSS funding to complete?  
Yes  
If yes, what would be the anticipated source(s) and timeline(s) for securing funding?  
For the initial analysis we are using financial support I obtained from our Cancer Center; however I am resubmitting an R21 that is due on March 16, 2019 that will include CCSS analysis along with other analysis.  

**Group: Does this project require contact of CCSS study subjects for:**

Additional self-reported information: No  
Biological samples: No  
Medical record data: No  
If yes to any of the above, please briefly describe.  

**Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)**

Second Malignancy:
Chronic Disease:
Psychology / Neuropsychology:
Genetics: Primary
Cancer Control:
Epidemiology / Biostatistics: Secondary

Section: Outcomes or Correlative Factors

Late mortality:
Second Malignancy:

Group: Health Behaviors
Tobacco:
Alcohol:
Physical activity:
Medical screening:
Other: Correlative Factors
If other, please specify: We will correlate hearing loss with self reported health, dizziness or vertigo, age, and dose of cisplatin.

Group: Psychosocial
Insurance:
Marriage:
Education:
Employment:
Other:
If other, please specify:

Group: Medical Conditions
Hearing/Vision/Speech: Primary
Hormonal systems:
Heart and vascular:
Respiratory:
Digestive:
Surgical procedures:
Brain and nervous system:
Other:
If other, please specify:

Group: Medications
Describe medications:
Cisplatin and/or cranial radiation.

Group: Psychologic/Quality of Life
BSI-18:
SF-36:
CCSS-NCQ:
PTS:
PTG:
Group: Other
Pregnancy and offspring:
Family history:
Chronic conditions (CTCAE v3):
Health status:

Group: Demographic
Age: Primary
Race: Primary
Sex: Primary
Other:
If other, please specify:

Group: Cancer treatment
Chemotherapy: Correlative Factors
Radiation therapy: Correlative Factors
Surgery:

Section: Anticipated Sources of Statistical Support
CCSS Statistical Center: Yes
Local institutional statistician:
If local, please provide the name(s) and contact information of the statistician(s) to be involved.
Will this project utilize CCSS biologic samples?: No
If yes, which of the following?:
If other, please explain:

Section: Other General Comments
Other General Comments:
We currently are working on a project entitled "GWAS of Childhood Cisplatin-induced Tinnitus and Meta-Analysis with Adult GWAS of Cisplatin-induced Tinnitus" Performing GWAS of self reported hearing loss will complement this analysis.
I agree to share this information with St. Jude: Yes